BICO GROUP AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.78 SEK | -14.39% |
|
-25.44% | -39.40% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 2.49B 230M | Sales 2025 * | 2.89B 267M | Capitalization | 3.2B 296M |
|---|---|---|---|---|---|
| Net income 2024 * | 14M 1.29M | Net income 2025 * | 131M 12.11M | EV / Sales 2024 * | 1.83 x |
| Net Debt 2024 * | 1.36B 126M | Net Debt 2025 * | 1.67B 154M | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
227
x | P/E ratio 2025 * |
24.4
x | Employees | 880 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.54% |
More Fundamentals
* Assessed data
More news
Latest transcript on BICO Group AB
More press releases
| 1 day | -14.39% | ||
| 1 week | -25.44% | ||
| Current month | -25.44% | ||
| 1 month | -22.46% | ||
| 3 months | -38.36% | ||
| 6 months | -13.48% | ||
| Current year | -39.40% |
1 week
34.20
51.15
1 month
34.2051.15
Current year
34.2061.12
1 year
23.3872.30
3 years
23.38630.00
5 years
23.38630.00
10 years
9.00630.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | Nov. 19 | |
Erik Gatenholm
FOU | Founder | 35 | 15-02-28 |
| Director of Finance/CFO | 39 | 21-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rolf Classon
CHM | Chairman | 79 | 22-04-25 |
John Mackay
BRD | Director/Board Member | 62 | 22-12-31 |
| Director/Board Member | 68 | 19-12-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.51% | 16 M€ | -3.93% | ||
| 0.00% | 34 M€ | +3.34% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 34.2 | -24.50% | 397 420 |
| 24-05-06 | 45.3 | -2.29% | 217,727 |
| 24-05-03 | 46.36 | -2.32% | 124,158 |
| 24-05-02 | 47.46 | +2.51% | 178,934 |
| 24-04-30 | 46.3 | -3.54% | 55,810 |
Delayed Quote Nasdaq Stockholm, May 07, 2024 at 03:13 am EDT
More quotes
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Companyâs operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Calendar
01:00am
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
45.3
SEK
Average target price
132.5
SEK
Spread / Average Target
+192.49%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -39.40% | 296M | |
| +8.06% | 219B | |
| +6.94% | 183B | |
| +13.54% | 136B | |
| -5.13% | 63.07B | |
| +11.59% | 51.28B | |
| +7.76% | 52.55B | |
| +1.14% | 41.21B | |
| +3.21% | 36.43B | |
| +26.11% | 31.87B |
- Stock Market
- Equities
- BICO Stock